Cormorant Asset Management as of Dec. 31, 2017
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 49 positions in its portfolio as reported in the December 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Nektar Therapeutics (NKTR) | 17.2 | $164M | 2.7M | 59.72 | |
| Anaptysbio Inc Common (ANAB) | 14.6 | $140M | 1.4M | 100.72 | |
| Apellis Pharmaceuticals (APLS) | 8.6 | $82M | 3.8M | 21.70 | |
| Omeros Corporation (OMER) | 5.3 | $51M | 2.6M | 19.43 | |
| Blueprint Medicines (BPMC) | 3.5 | $34M | 450k | 75.41 | |
| Myokardia | 3.5 | $34M | 800k | 42.10 | |
| Dicerna Pharmaceuticals | 3.5 | $33M | 3.7M | 9.03 | |
| Inflarx Nv (IFRX) | 3.1 | $30M | 1.4M | 20.95 | |
| Theravance Biopharma (TBPH) | 2.6 | $25M | 900k | 27.89 | |
| Juno Therapeutics | 2.6 | $25M | 550k | 45.71 | |
| Mirati Therapeutics | 2.4 | $23M | 1.2M | 18.25 | |
| Quotient | 2.3 | $22M | 4.5M | 4.95 | |
| Avexis | 2.3 | $22M | 200k | 110.67 | |
| Proteostasis Therapeutics In | 2.0 | $19M | 3.3M | 5.83 | |
| Argenx Se (ARGX) | 1.9 | $18M | 290k | 63.14 | |
| Quanterix Ord (QTRX) | 1.9 | $18M | 848k | 21.47 | |
| G1 Therapeutics | 1.9 | $18M | 898k | 19.84 | |
| Neurocrine Biosciences (NBIX) | 1.6 | $16M | 200k | 77.59 | |
| Bluebird Bio (BLUE) | 1.5 | $14M | 80k | 178.10 | |
| Aclaris Therapeutics (ACRS) | 1.4 | $14M | 550k | 24.66 | |
| Clearside Biomedical (CLSD) | 1.4 | $14M | 1.9M | 7.00 | |
| Ascendis Pharma A S (ASND) | 1.3 | $12M | 300k | 40.06 | |
| Audentes Therapeutics | 1.1 | $11M | 338k | 31.25 | |
| Abeona Therapeutics | 0.9 | $9.1M | 575k | 15.85 | |
| Array BioPharma | 0.9 | $9.0M | 700k | 12.80 | |
| Protagonist Therapeutics (PTGX) | 0.9 | $8.3M | 400k | 20.80 | |
| Biohaven Pharmaceutical Holding | 0.8 | $8.0M | 298k | 26.98 | |
| Wave Life Sciences (WVE) | 0.7 | $7.1M | 202k | 35.10 | |
| Zai Lab (ZLAB) | 0.7 | $7.1M | 333k | 21.23 | |
| Sangamo Biosciences (SGMO) | 0.7 | $6.6M | 400k | 16.40 | |
| Gemphire Therapeutics | 0.7 | $6.4M | 800k | 7.95 | |
| Reata Pharmaceuticals Inc Cl A | 0.6 | $5.7M | 200k | 28.32 | |
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.6 | $5.5M | 300k | 18.46 | |
| Mersana Therapeutics (MRSN) | 0.5 | $4.9M | 296k | 16.43 | |
| Jounce Therapeutics | 0.5 | $4.7M | 367k | 12.75 | |
| Trillium Therapeutics, Inc. Cmn | 0.5 | $4.4M | 600k | 7.30 | |
| Intec Pharma | 0.4 | $4.2M | 810k | 5.15 | |
| Marinus Pharmaceuticals | 0.4 | $4.1M | 500k | 8.16 | |
| Ardelyx (ARDX) | 0.4 | $3.8M | 573k | 6.60 | |
| Heron Therapeutics (HRTX) | 0.4 | $3.6M | 200k | 18.10 | |
| Minerva Neurosciences | 0.4 | $3.7M | 608k | 6.05 | |
| Contrafect | 0.4 | $3.6M | 3.6M | 1.01 | |
| Acceleron Pharma | 0.3 | $3.2M | 75k | 42.44 | |
| Syros Pharmaceuticals | 0.3 | $2.9M | 296k | 9.73 | |
| Ovid Therapeutics (OVID) | 0.2 | $2.2M | 224k | 9.87 | |
| Cellectar Biosciences Equity Warrants *w | 0.0 | $4.8k | 53k | 0.09 | |
| Oncobiologics | 0.0 | $40k | 31k | 1.31 | |
| Oncobiologics Inc *w exp 02/18/201 | 0.0 | $13k | 417k | 0.03 | |
| Oncobiologics Inc *w exp 05/18/201 | 0.0 | $8.3k | 417k | 0.02 |
